2.725

5.71% -0.165

Incannex Healthcare Limited ADR (IXHL)

Overview News Price History Why IXHL Down? Discussions Forecast

Incannex Healthcare Limited ADR stock is currently priced at $2.725, with a 24-hour trading volume of 11,855. It has seen a -5.71% decreased in the last 24 hours and a -22.80% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $2.80 pivot point. If it approaches the $2.66 support level, significant changes may occur.

Previous Close:

$2.89

Open:

$2.93

24h Volume:

11,855

Market Cap:

$45.87M

Revenue:

Net Income/Loss:

P/E Ratio:

-14.83

EPS:

-0.1837

Net Cash Flow:

1W Performance:

+20.58%

1M Performance:

-22.80%

6M Performance:

+161.79%

1Y Performance:

+32.28%

1D Range:

$2.75

$2.94

52W Range:

$0.80

$12.68

Incannex Healthcare Limited ADR Stock (IXHL) Company Profile

Name

Incannex Healthcare Limited ADR

Sector

Healthcare (1200)

Industry

Drug Manufacturers - Specialty & Generic (4)

Phone

Address

207/11 Solent Circuit, Norwest, Sydney

Employee

Twitter

Next Earnings Date

Latest SEC Filings

IXHL's Discussions on Twitter

Incannex Healthcare Limited ADR Stock (IXHL) Latest News

Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Benzinga

Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation

GlobeNewswire Inc.

Clarion Clinics Open for Psychedelic-Assisted Treatments

GlobeNewswire Inc.

Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis

GlobeNewswire Inc.

Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences

GlobeNewswire Inc.

Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

GlobeNewswire Inc.

Incannex Healthcare Limited ADR Stock (IXHL) Financials Data

There is no financial data for Incannex Healthcare Limited ADR (IXHL). Check out other stocks for more information.

Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea; and Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Sydney, Australia.